A new era of cancer screening


Wednesday, June 12th, 2024 | 11:00 AM - 12:00 PM CT

As cancer rates rise, it's imperative that more cases are caught earlier, when they may be more treatable. But today's single-organ cancer screening paradigm won't be enough to stop cancer from becoming the anticipated No. 1 cause of death by 2030.

Increasingly, experts are optimistic that multi-cancer early detection (MCED) testing will enable progress in the field by catching more cases in their earliest stages. Innovative developments are underway that may soon usher in a new era for cancer screening. 

Join Tomasz Beer, MD, a globally recognized expert in early cancer detection, for a conversation on how multi-cancer early detection testing is addressing unmet screening needs, and its potential to reduce the overall burden of cancer. 

Learning points:
 
  • What we’ve learned about the potential clinical value of MCED testing from prospective clinical trials
  • Details on a robust multi-biomarker class approach to MCED test design to help maximize its potential clinical benefit
  • Key considerations for the future of MCED testing

Presenter:

Tomasz Beer - Sarah Simon

Tomasz M. Beer, MD, FACP

Chief Medical Officer and VP | Multi-cancer Early Detection | Exact Sciences

 

By registering, you agree to Becker's Healthcare terms of service and privacy policy.

I would like to also add the following learning opportunities to my registration:

  • Cedars-Sinai, Carle Health + more reveal a blueprint for AI adoption and driving ROI, here. - February 6th at 1:00 PM CT - Learn Now
  • ED boarding: Mount Sinai shares the hard truths + real solutions with Becker's Molly Gamble, here. - February 4th at 12:00 PM CT - Learn Now
  • Behavioral health is under pressure. How some leaders are cutting claims denials by 25% — here. - January 29th at 12:00 PM CT - Learn Now
  • Behavioral health 2025: Find insights from the new Becker's survey here. - Read Now
  • Dental + DSO Virtual Event - Thursday, January 23rd, 2025 - Learn Now